Biodel's Steiner to retire, remains board member
DANBURY, Conn. — A drug maker specializing in the treatment of diabetes announced the retirement of its chief scientific officer.
Biodel this week said Solomon Steiner, who is a company co-founder, will remain on the company's board of directors. Prior to holding his chief scientific officer position, Steiner was chairman, president and CEO of Biodel from its inception in late 2003 through March of this year, at which point Errol De Souza was appointed to be the company's president and chief executive, and Charles Sanders was named board chairman.
"In 2003, I started Biodel with a vision of making a difference in patients' lives," Steiner said. "Over the course of seven years, I have had the privilege of assembling a talented scientific team and working with them to create a portfolio of product candidates, which continues to grow. I am confident that with Errol De Souza's leadership, this team will be able to bring these important innovations to market for the benefit of patients everywhere. I look forward to continuing to advise Biodel as a member of the board of directors."